with

Manulife Investments Targets Under-researched Singapore Small and MidCaps With New Income Strategy

Strategy developed under MAS EQDP to capture under-researched opportunities in Singapore equitiesSINGAPORE, March 3, 2026 /PRNewswire/ -- Manulife Investments today…

3 days ago

3iQ Announces Successful Closing of Previously Announced Transaction with Coincheck Group N.V.

TORONTO, March 2, 2026 /PRNewswire/ -- 3iQ Corp. ("3iQ"), a global pioneer in institutional digital asset investment solutions, is pleased…

3 days ago

MEXC Launches Commodity Zero-Fee Gala with $1 Million in Trading Rewards

VICTORIA, Seychelles, March 2, 2026 /PRNewswire/ -- MEXC, the world's fastest-growing digital asset exchange and a pioneer of true zero-fee…

3 days ago

KuCoin Enhances Lite Mode With Earn and Feed, Supporting Confident Entry Into Crypto and Broader Adoption

PROVIDENCIALES, Turks and Caicos Islands, March 2, 2026 /PRNewswire/ -- KuCoin, a leading global crypto platform built on trust, today announced…

3 days ago

BRITISH ROYAL MINT CELEBRATES 30 YEARS OF GIRL POWER WITH OFFICIAL SPICE GIRLS COMMEMORATIVE COIN

LLANTRISANT, Wales, March 2, 2026 /PRNewswire/ -- If you really really really wanna own a piece of pop history, you better…

3 days ago

Starlight Investments Expands Asia-Pacific Presence with Senior Hire in Korea

Starlight appoints TK Gong as Vice President, Global Markets, Asia and the Pacific and opens office in SeoulTORONTO and SEOUL, South Korea, March 3,…

3 days ago

Pediatric Home Service Partners with Morgans to Expand Prescribed Pediatric Extended Care Services in Texas with New Center, Morgans Wonder Care

SAN ANTONIO, March 02, 2026 (GLOBE NEWSWIRE) -- Pediatric Home Service (PHS), a national provider of comprehensive pediatric healthcare, is…

3 days ago

HONOR Advances Its AI Vision at MWC 2026 with Robot Phone, Humanoid Robot and Magic V6

From robotics innovation to flagship devices, HONOR expands its AI device ecosystem at MWC 2026BARCELONA, Spain, March 2, 2026 /PRNewswire/…

3 days ago

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and…

4 days ago